Genetic association between APOE*4 and neuropsychiatric symptoms in patients with probable Alzheimer's disease is dependent on the psychosis phenotype

Table 2 Frequency of AD subjects with at least one neuropsychiatric symptom in a given domain, and relative risk for the symptom in that domain by one and two APOΕ 4 alleles versus no APOE* *4 allele

Domain	No *APOΕ**4 allele (n=348)	One *APOΕ**4 allele (n=368)	Two *APOΕ**4 alleles (n=74)	P*
Hallucinations (2 items)
Frequency (%)	53 (15%)	42 (11%)**	4 (5%)
RR 95% CI	1.00	0.71 (0.50, 0.97)	0.32 (0.00, 0.74)	0.0066
Delusions (10 items)
Frequency (%)	241 (69%)	259 (70%)	40 (54%)
RR 95% CI	1.00	1.05 (0.96, 1.15)	0.87 (0.72, 1.07)	0.160
Agitation (3 items)
Frequency (%)	150 (43%)	147 (40%)	30 (41%)
RR 95% CI	1.00	0.93 (0.79, 1.11)	1.04 (0.77, 1.35)	0.628
Aberrant motor behavior (2 items)
Frequency (%)	196 (56%)	195 (53%)	35 (47%)
RR 95% CI	1.00	0.94 (0.83, 1.07)	0.86 (0.67, 1.08)	0.382

*Generalized linear models of domain on the number of APOΕ *4 alleles (treated as categorical) with log link, and error modeled as Gaussian and with the following covariates: age, duration of illness, MMSE, CDR, gender, and education.
**2 subjects with 1 APOE 4 allele were missing all hallucination domain data.
Abbreviations: APOE, apolipoprotein E; RR, relative risk; CI, confidence interval; MMSE, Mini-Mental State Examination; CDR, Clinical Dementia Rating scale; BRSD, Behavioral Rating Scale for Dementia.

ISSN: 1744-9081